CellMax Life Inc (合度精密生物科技) yesterday launched a blood-testing service in Taiwan that focuses on screening for early-stage cancer.
The company’s flagship product, CellMax CRC-Protect, is a multi-biomarker blood test aimed at the early detection of colorectal cancer.
The product has been used by more than 500 patients at a number of local hospitals, including Linkou Chang Gung Memorial Hospital (林口長庚紀念醫院).
“We aim to transform cancer care away from expensive, intractable late stages to early, more treatable stages,” CellMax Life co-founder and chief operating officer Atul Sharan told a news conference in Taipei yesterday.
Much of the biotechnology sector focuses on expensive late-stage drugs that might not be accessible in developing countries, while survival rates for patients with late-stage cancer diminish rapidly, Sharan added.
The company’s proprietary CMx technology platform screens for cancer by detecting traces of circulating early-stage tumor cells that are shed from the primary tumor site into the bloodstream, CellMax science team chief Shao Hung-jen (邵宏仁) said.
Abnormal cells should be detected by the screening product before they turn into precancerous cells and metastasize, Shao said.
The platform uses a biomimetic, lipid-bilayer coated microfluidic chip to identify circulating tumor cells cells in patients’ blood samples, Shao said.
As the test requires a blood sample, it is an attractive option for patients who are averse to fecal occult blood tests, stool samples or colonoscopies, Shao said.
However, the test is not intended to replace existing examinations, but is designed to be used as an additional diagnostic tool by physicians, Shao said.
A woman said in a testimonial video that after using a CellMax screening product and consulting her physician, she agreed to have intestinal surgery that removed eight polyps and minimized her chances of contracting colon cancer.
Chao recommended that people who are at high risk of developing colon cancer undergo annual screening, adding that each of the firm’s tests costs about NT$15,000.
CellMax’s other products include testing of genetic risk, liquid biopsies and recurrence monitoring.
The company also announced US$9 million in series A-1 venture funding to scale commercial operations of its blood test product portfolio.
The funding was led by Silicon Valley-based Artiman Ventures and several Taiwanese venture investors, including Acer founder and former chairman Stan Shih (施振榮).
The company has so far accumulated US$14 million in venture capital.
The US dollar was trading at NT$29.7 at 10am today on the Taipei Foreign Exchange, as the New Taiwan dollar gained NT$1.364 from the previous close last week. The NT dollar continued to rise today, after surging 3.07 percent on Friday. After opening at NT$30.91, the NT dollar gained more than NT$1 in just 15 minutes, briefly passing the NT$30 mark. Before the US Department of the Treasury's semi-annual currency report came out, expectations that the NT dollar would keep rising were already building. The NT dollar on Friday closed at NT$31.064, up by NT$0.953 — a 3.07 percent single-day gain. Today,
‘SHORT TERM’: The local currency would likely remain strong in the near term, driven by anticipated US trade pressure, capital inflows and expectations of a US Fed rate cut The US dollar is expected to fall below NT$30 in the near term, as traders anticipate increased pressure from Washington for Taiwan to allow the New Taiwan dollar to appreciate, Cathay United Bank (國泰世華銀行) chief economist Lin Chi-chao (林啟超) said. Following a sharp drop in the greenback against the NT dollar on Friday, Lin told the Central News Agency that the local currency is likely to remain strong in the short term, driven in part by market psychology surrounding anticipated US policy pressure. On Friday, the US dollar fell NT$0.953, or 3.07 percent, closing at NT$31.064 — its lowest level since Jan.
Hong Kong authorities ramped up sales of the local dollar as the greenback’s slide threatened the foreign-exchange peg. The Hong Kong Monetary Authority (HKMA) sold a record HK$60.5 billion (US$7.8 billion) of the city’s currency, according to an alert sent on its Bloomberg page yesterday in Asia, after it tested the upper end of its trading band. That added to the HK$56.1 billion of sales versus the greenback since Friday. The rapid intervention signals efforts from the city’s authorities to limit the local currency’s moves within its HK$7.75 to HK$7.85 per US dollar trading band. Heavy sales of the local dollar by
The Financial Supervisory Commission (FSC) yesterday met with some of the nation’s largest insurance companies as a skyrocketing New Taiwan dollar piles pressure on their hundreds of billions of dollars in US bond investments. The commission has asked some life insurance firms, among the biggest Asian holders of US debt, to discuss how the rapidly strengthening NT dollar has impacted their operations, people familiar with the matter said. The meeting took place as the NT dollar jumped as much as 5 percent yesterday, its biggest intraday gain in more than three decades. The local currency surged as exporters rushed to
RSS